Effects Of β₂ Adrenoceptor Genetic Polymorphisms On Formoterol Bronchodilator Response In Patients With COPD

Objective To investigate the relation of genetic polymorphisms ofβ₂ adrenoceptor (β₂AR)at codons 16 and 17(A rg16Gly+Gln27Glu)on longacting bronchodilator response in patients with COPDMethods All patients with COPD that initially numbered 126 individuals who were randomized underwent assessments of lung function;genotyping for polymorphisms of the beta(2)AR at codons 16 and 17 was performed.After one month,these patients who have inhaled formoterol were tested lung function again.To compare relation of differentβ₂AR genetic polymorphism and formoterol bronchodilator response.Results Patients who had homozygous or heterozygous genotypes containing the arginine16 polymorphism(Arg16/Arg16(n=37),Arg16/Gly16(n=41))had lower bronchodilator response after inhaling formoterol(n=19 and n=21 respectively), however,the homozygous glycine16 genotype Gly16/Gly16(n=48)had a significant greater bronchodilator response(n=41 P＜0.05).But no independent associations were observed between theβ₂AR genetic polymorphism in 27 position and bronchodilator response.Meanwhile,the most common Arg16Gln27 haplotypes reduced bronchodilator response remarkably(P＜0.01).Conclusionsβ₂ adrenoceptor genetic polymorphisms may influence longactingβ₂ adrenoceptor agonist reactivity.So the clinical effects of different longactingβ₂ adrenoceptor agonist can be explained.